Letter to the Editor
Carisoprodol Should be Taken Off the Market
To the Editor:
In an editorial in the February edition of the Southern Medical Journal, Reeves and Burke1 advocate that carisoprodol (Soma® Meda Pharmaceuticals, Inc; Somerset, NJ) should become a controlled substance. During the last few years, three other papers have been published by American researchers addressing the possible abuse of this centrally acting muscle relaxant.2–4 The research paper accurately points to the abuse potential of carisoprodol4 and the increasing extent of this problem,2,3 arguing that carisoprodol should be a controlled substance.1,2 We follow this research and debate with interest. For several years and on several occasions these researchers, along with other US data, have provided us with valuable information in our own research into this field. We would therefore like to offer a comment on these valuable publications.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view your purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.